BFRI (Biofrontera) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BFRI Biofrontera Inc BFRI
31 GF Score
Price $1.17
GF Value $0.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofrontera Short-term investments?

Short-term investments only applies to insurance companies.

BFRI
31GF Score
Biofrontera Inc BFRI
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $1.17 is trading 129.8% above its estimated GF Value™ of $0.51. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Short-term investments:
  • GF Value™: $0.51 vs. price of $1.17 (129.8% above fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology, specifically photodynamic therapy (PDT). Its lead product, Ameluz (aminolevulinic acid hydrochloride) gel, is approved in the United States for the treatment of actinic keratoses, a common precancerous skin condition, when used with the company's BF-RhodoLED and RhodoLED XL lamps. The company also markets Xepi (ozenoxacin) cream for impetigo. Biofrontera commercializes these products primarily through a direct specialty sales force targeting dermatologists and dermatology clinics across the United States, and its revenue is generated almost entirely within the U.S. market. The company was originally founded in Germany and operates as a subsidiary of Biofrontera AG, from which it licenses the rights to its core PDT products.
31GF Score

Get the complete analysis for BFRI

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price
$0.51
GF Value